Feed/Companies/VectorY Therapeutics

VectorY Therapeutics

As of 14 Nov 2026, VectorY Therapeutics has raised $82.9M across 1 verified round on record (amounts in other currencies converted to USD), plus 2 rounds still being checked; latest: €74.5 million ($83.5 million) Series A, announced 11 Nov 2026.

BUILT ON

A clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases

vectorytx.comLinkedInAmsterdamBiotechFounded 2020

LATEST ROUND

Series A

$82.9M · 2026-11-11

RAISED ON RECORD · USD

$82.9M

across 1 verified round · plus 2 rounds still being checked

INVESTORS

3 leads

SOURCES

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Rounds

[ 3 ]

Series A

$82.9M · 2026-11-11

lead not stated

Series A

$137.6M · 2023-11-13

[ HISTORY ]

led by EQT Life Sciences, Forbion Growth Opportunities Fund

Seed

$37.5M · 2021-06-15

[ HISTORY ]

led by Forbion

Round	Amount	Announced	Lead	Buzz
Series A	$82.9M €234.5M financing total €74.5 million ($83.5 million)	2026-11-11	not stated	1 person on X · 10 outlets. #30 in Trending
10 sources · checked 1 time, last 2d ago [ VERIFIED · CORRECTED ] read against 1 of 10 sources This is a weekly roundup; the publication date is used for the covered week with week precision, not as an exact announcement day.

On

1 person on 10 outlets

INTJ投资笔记@intjyan3d ago💰 生物医药：VectorY Therapeutics 融资 €7450万（约$8350万），Angelini Ventures、Invest-NL、EIB 新进，Forbion、EQT Life Sciences、礼来等老股东跟投，用于 ALS 药物 VTx-002 的临床推进。 VectorY raises €74.5M ($83.5M) to advance its ALS and Huntington's antibody gene-therapy pipeline. #资金动向 #融资 #Funding #Biotech" / X

Found on X with Firecrawl search

Company research

Fetched today

VectorY is an Amsterdam-based biotechnology company developing one-time AAV-delivered antibody treatments for people with neurodegenerative diseases.

Founders

Carlo Incerti · Co-Founder and Chairman of the Board of VectorY
Before VectorY, he was Chief Medical Officer of Sanofi Genzyme and had worked in the gene-therapy field for more than 30 years.
Pavlina Konstantinova · Co-founder
Anthony Newcombe · Co-founder
Barbara Sanders · Co-founder, Chief Operating Officer and Site Head
Before and alongside her work at VectorY, she built more than 10 years of viral-vector-development experience in large pharmaceutical and biotechnology companies, contributing to vaccines including the commercialized Ebola vaccine Zabdeno.
Sander van Deventer
He co-founded Amsterdam Molecular Therapeutics, now uniQure, later serving as its CSO, CMO and CEO, and is also a co-founder and Operating Partner of Forbion.

Checked against 10 sources today

SOURCES

Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$137.6M €129 million ($138 million)	2023-11-13	EQT Life Sciences, Forbion Growth Opportunities Fund	No recent discussion
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source Sources agree. The release names “another known investor” but does not identify it. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: vectorytx.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

Seed [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$37.5M €31 million	2021-06-15	Forbion	No recent discussion
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source Removed BioGeneration Ventures (BGV) · no source places them in this round The release identifies Forbion and an unnamed leading global investment firm as co-leads; BGV and Eli Lilly joined the syndicate. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: vectorytx.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

VectorY Therapeutics

Company

Rounds

Sources

Profile

Investors

VectorY Therapeutics

Rounds

On

Company research

Sources

Series A$82.9M2026-11-1110 sources

Series A$137.6M2023-11-131 source

Seed$37.5M2021-06-151 source

Investors

Series A$82.9M2026-11-1113 investors

Series A$137.6M2023-11-136 investors

Seed$37.5M2021-06-153 investors